Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label Phase I/II Study of MEK Inhibitor GSK1120212 in Relapsed or Refractory Leukemias
2009-017376-25Phase 2Completed
- Sponsor
- GSK
- Start
- Feb 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of trametinib in leukemia and acute myeloid leukemia (AML), sponsored by GSK. Primary endpoints: Safety and tolerability (Phase I component), Pharmacokinetics (Phase I/II) and 2 more. Started Feb 2011; status: completed.
02
Drugs
trametinib
03
Conditions
leukemiaacute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2009-017376-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-017376-25.